Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Post by Rishikon Apr 07, 2020 10:37am
107 Views
Post# 30886444

Plasma therapy is helping Covid-19 patients

Plasma therapy is helping Covid-19 patients

Canada begins clinical trial of experimental COVID-19 treatment using plasma from recovered individuals

A team of blood transfusion experts from across Canada is planning the world’s largest clinical trial of a potential treatment for COVID-19.

The study, which will involve 1,000 patients from across the country, will include at least 40 Canadian hospitals, and is being overseen by doctors from the University of Montreal, University of Ottawa, University of Toronto, McMaster and the University of British Columbia, among other schools.

The experimental treatment involves injecting antibody-rich plasma from patients who have recovered from the virus into those who are still infected. This approach has only been tried in small trials in China, Singapore, South Korea and the U.S. It is part of a global race to find a treatment for the disease, with researchers also focusing on antivirals and medications used to treat malaria.




<< Previous
Bullboard Posts
Next >>